For weight management in the elderly, there is an emerging evidence pointing to the fact that this category can have an excessive lean muscle loss and this is the challenge posed with some of the newer medications. This is an alarming concern as there is a rapid progression of the muscle and bone loss for the weight management candidates over the age of 60. There are two favourable treatment options; one, combining glucagon or amylin with the GLP-1 receptor agonists or the second, which is using the myostatin-activin pathway inhibitors.
Regeneron is a leading biotechnology company that was founded by physician-scientists since 1988 and have invented medicines that are life-transforming for serious diseases. Trevogrumab (a myostatin antagonist) and Garetosmab (An activin-A antagonist) are two such drugs that work by reducing the activity of myostatin and activin-A.
The company are working on the experimental drugs and expect a full data from the study later this year!
“Regeneron (REGN.O), opens new tab said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk’s (NOVOb.CO), opens new tab popular obesity drug Wegovy in a mid-stage trial. In the 599-patient study, those on Wegovy alone lost about 7.9 pounds of muscle, while those on a combination of Regeneron’s trevogrumab and Wegovy lost up to 4.2 pounds. The combination helped patients shed up to 11.3% of their body weight compared with 10.4% for those on only Wegovy. The results mark an early win for Regeneron in the race against nearly a dozen companies to develop obesity treatments that preserve muscle, as they vie for a share of the potential $150 billion weight-loss drug market.”
Via Reuters

Sources:






Leave a comment